Clinical Observation of the Patients with Oral Adverse Events During Cancer Chemotherapy Including Molecular Targeted Drugs

AKIYAMA Kaoru, SAITO Masahiro, KOMIYAMA Yuske, TSUCHIDA Shuji, OKUBO Maki, KAWAMATA Hitoshi

doi:10.6014/jjsom.22.1

Bibliographic Information

Other Title

分子標的治療薬を含むがん化学療法施行中の口腔内有害事象発症例の検討
ブンシヒョウテキチリョウヤクオフクムガンカガクリョウホウシコウナカノクチクウナイユウガイジショウハッショウレイノケントウ

Published: 2016

DOI

10.6014/jjsom.22.1

Publisher: Japanese Society of Oral Medicine

Search this article

Description

There was a few study concerning the oral adverse events during cancer therapy with molecular targeted drugs. Among the patients referred to our oral care unit from April 2007 to March 2014, 23 patients who were treated with molecular targeted drugs showed 27 oral adverse events. We examined the details of the oral adverse events and the causal drugs on these 23 patients. Ten patients were treated with small molecule drugs, while 17 patients were treated with monoclonal antibody drugs. The small molecule drugs were used singly, whereas the monoclonal antibody drugs were always used with conventional cytotoxic chemotherapeutic agents. Oral mucositis was observed in all 23 patients (27 events), and taste disorder was seen in 4 patients (4 events). All patients received the professional oral management, then they completed their cancer chemotherapy in the designated period. Because the single use of sunitinib (multi-kinase inhibitor) could lead oral mucositis, an intensive oral management before sunitinib treatment should be necessary.

Journal

Journal of Japanese Society of Oral Medicine

Journal of Japanese Society of Oral Medicine 22 (1), 1-7, 2016

Japanese Society of Oral Medicine

Keywords

Details 詳細情報について

Export

Report a problem